WO2002079492A8 - Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators - Google Patents

Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Info

Publication number
WO2002079492A8
WO2002079492A8 PCT/US2002/004915 US0204915W WO02079492A8 WO 2002079492 A8 WO2002079492 A8 WO 2002079492A8 US 0204915 W US0204915 W US 0204915W WO 02079492 A8 WO02079492 A8 WO 02079492A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
angiogenesis
diagnosis
screening
compositions
Prior art date
Application number
PCT/US2002/004915
Other languages
French (fr)
Other versions
WO2002079492A2 (en
Inventor
Richard Murray
Richard Glynne
Susan R Watson
Natasha Aziz
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to CA002438030A priority Critical patent/CA2438030A1/en
Priority to EP02726581A priority patent/EP1418943A1/en
Priority to AU2002257004A priority patent/AU2002257004A1/en
Priority to JP2002578493A priority patent/JP2004531249A/en
Publication of WO2002079492A2 publication Critical patent/WO2002079492A2/en
Publication of WO2002079492A8 publication Critical patent/WO2002079492A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
PCT/US2002/004915 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators WO2002079492A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002438030A CA2438030A1 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
EP02726581A EP1418943A1 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002257004A AU2002257004A1 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
JP2002578493A JP2004531249A (en) 2001-02-14 2002-02-14 Method for diagnosing angiogenesis, composition, and method for screening angiogenesis modulator

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US78435601A 2001-02-14 2001-02-14
US09/784,356 2001-02-14
US79139001A 2001-02-22 2001-02-22
US09/791,390 2001-02-22
US28547501P 2001-04-19 2001-04-19
US60/285,475 2001-04-19
US31002501P 2001-08-03 2001-08-03
US60/310,025 2001-08-03
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33424401P 2001-11-29 2001-11-29
US60/334,244 2001-11-29

Publications (2)

Publication Number Publication Date
WO2002079492A2 WO2002079492A2 (en) 2002-10-10
WO2002079492A8 true WO2002079492A8 (en) 2004-03-25

Family

ID=27559580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/004915 WO2002079492A2 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Country Status (5)

Country Link
EP (1) EP1418943A1 (en)
JP (1) JP2004531249A (en)
AU (1) AU2002257004A1 (en)
CA (1) CA2438030A1 (en)
WO (1) WO2002079492A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9182405B2 (en) 2006-04-04 2015-11-10 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9494598B2 (en) 2006-04-04 2016-11-15 Singulex, Inc. Highly sensitive system and method for analysis of troponin

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AU2002249787A1 (en) 2000-10-25 2002-08-19 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
US7622443B2 (en) 2002-04-26 2009-11-24 California Institute Of Technology Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
AU2003268494A1 (en) * 2002-09-11 2004-04-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP2233926A3 (en) 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
US20060216286A1 (en) 2003-04-25 2006-09-28 Yasuaki Ito Novel screening method
US7267950B2 (en) * 2003-05-01 2007-09-11 Veridex, Lcc Rapid extraction of RNA from cells and tissues
US7833733B2 (en) 2003-06-09 2010-11-16 The University Of British Columbia Methods for detecting and treating cancer
US9309323B2 (en) 2003-06-09 2016-04-12 The University Of British Columbia Methods for detecting and treating cancer
JP2007527704A (en) * 2003-06-30 2007-10-04 ジェノバ・リミテッド Secreted polypeptide species associated with cardiovascular disorders
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
DE10340373A1 (en) * 2003-08-30 2005-03-24 Henkel Kgaa Determining the hair cycle in humans, by measuring protein or mRNA levels and classification as anagenic or catagenic, also for screening therapeutic or cosmetic agents that affect hair growth
JP2005073621A (en) * 2003-09-01 2005-03-24 Japan Science & Technology Agency Marker for cerebral tumor and method for diagnosing cerebral tumor
WO2005069855A2 (en) 2004-01-13 2005-08-04 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
JP4857259B2 (en) 2004-03-24 2012-01-18 アボット バイオセラピューティクス コーポレイション Use of anti-α5β1 antibodies to inhibit cancer cell growth
EP1743944A4 (en) 2004-04-23 2011-01-05 Takeda Pharmaceutical Novel method of screening
WO2005113788A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
US8067189B2 (en) * 2005-09-01 2011-11-29 Bristol-Myers Squibb Company Methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators by measuring the level of collagen type IV
WO2007095353A2 (en) * 2006-02-14 2007-08-23 Geisinger Clinic Gpcrs as angiogenesis targets
US20090028793A1 (en) * 2006-02-22 2009-01-29 Philogen Spa Vascular Tumor Markers
ES2544957T3 (en) 2006-03-21 2015-09-07 Genentech, Inc. Combined therapy involving alpha5beta1 antagonists
SI2200700T1 (en) 2007-09-26 2016-04-29 Genentech, Inc. Novel antibodies
EP2216399A1 (en) 2009-01-30 2010-08-11 Université de la Méditerranée Human soluble CD146, preparation and uses thereof
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
JP5678045B2 (en) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド High sensitivity biomarker panel
CA2767442A1 (en) 2009-07-08 2011-01-13 Actgen Inc. Antibody having anti-cancer activity
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9182405B2 (en) 2006-04-04 2015-11-10 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9494598B2 (en) 2006-04-04 2016-11-15 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2

Also Published As

Publication number Publication date
EP1418943A1 (en) 2004-05-19
CA2438030A1 (en) 2002-10-10
AU2002257004A1 (en) 2002-10-15
WO2002079492A2 (en) 2002-10-10
JP2004531249A (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2002079492A8 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU6902200A (en) Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002252144A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
WO2003022987A9 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002306918A1 (en) Methods of modulating angiogenesis
AU2002242996A1 (en) Spiroisoquinoline compounds, methods for their preparation and intermediates
AU2002249467A1 (en) Screening method
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002367145A1 (en) Remedies for anorexia or lifestyle-related diseases and method of screening the same
AU2002332696A1 (en) Solid support dirhodium catalyst compositions and methods for making and using same
AU2002307413A1 (en) Modulators of angiogenesis
AU2002331753A1 (en) Dirhodium catalyst compositions and methods for using same
AU2002353772A1 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2002348191A1 (en) Method and composition for the modulation of angiogenesis
AU2002354206A1 (en) Method of screening drug
AU2002347578A1 (en) Process for the preparation of dronedarone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2438030

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002578493

Country of ref document: JP

Ref document number: PA/A/2003/007251

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002726581

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

D17 Declaration under article 17(2)a
WWP Wipo information: published in national office

Ref document number: 2002726581

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2002726581

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002726581

Country of ref document: EP